Search

Displaying results 1781 - 1790 of 10000 in total
  1. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. … Regorafenib is an orally-administered inhibitor of multiple kinases.

  2. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    in thermo-regulation. … [L53798] By blocking receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which are hyperactivated due to estrogen decline in menopause, elinzanetant modulates neuronal activity involved

    Synonyms: 2-(3,5-bis(trifluoromethyl)phenyl)-n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-7-(hydroxymethyl)hexahydropyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,2-dimethylpropanamide, Benzamide, 3-(5-methyl-2-tbenzeneacetamide, n-(4-(4-fluoro-2-methylphenyl)-6-((7s,9as)-hexahydro-7-(hydroxymethyl)pyrazino(2,1-c)(1,4)oxazin-8(1h)-yl)-3-pyridinyl)-n,.alpha.,.alpha.
  3. Drug

    Fenretinide

    go.drugbank.com/drugs/DB05076
    Investigational

    A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N-(4-hydroxyphenyl)all-trans retinamide
  4. Drug

    Casirivimab

    go.drugbank.com/drugs/DB15941
    ApprovedInvestigational

    [A221495] On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older. … [L23524] In November 2021, the same indication was approved by the EMA.

  5. Drug

    Varicella zoster vaccine (recombinant)

    go.drugbank.com/drugs/DB13924
    ApprovedInvestigational

    The main immunological component of Shingrix vaccine is glycoprotein E (gE), a protein found on the surface of varicella zoster virus (VZV). … Clinical trials for Shingrix have shown greater than 90% efficacy in adults aged 50 and older, with 89% efficacy in preventing postherpetic neuralgia in patients 70 years and older and 91% efficacy in

    Synonyms: gE recombinant Varicella zoster virus (VZV) glycoprotein E, Recombinant Varicella zoster virus (VZV) glycoprotein E
  6. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    [L4563] In particular, cenegermin was granted Priority Review designation, under which the FDA’s goal is to take action on an application within six months of application filing where the agency determines … [L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition and its associated sequelae on an individual patient can be debilitating.

  7. Drug

    Vonoprazan

    go.drugbank.com/drugs/DB11739
    ApprovedInvestigational

    [A253707] In February 2015, vonoprazan was first marketed in Japan for the treatment of acid-related disorders and as an adjunct to _Helicobacter pylori_ (_H. pylori_) eradication. … [A253702] In May 2022, the FDA approved the use of vonoprazan in a co-packaged product containing amoxicillin and clarithromycin for the treatment of _H. pylori_ infection.

    Synonyms: 1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-N-methylmethanamine
  8. Drug

    Nonivamide

    go.drugbank.com/drugs/DB11324
    Approved

    Nonivamide is found in herbs and spices. It is an alkaloid from the Capsicum species. … This drug has been studied in combination with Nicarboxil in the treatment of lower back pain [L2642].

    Synonyms: N-Vanillylnonamide, N-Nonanoyl vanillylamide
  9. Drug

    Binimetinib

    go.drugbank.com/drugs/DB11967
    ApprovedInvestigational

    [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients … with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.

  10. Drug

    Rivastigmine

    go.drugbank.com/drugs/DB00989
    ApprovedInvestigational

    Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

    Categories: Compounds used in a research, industrial, or household settingProducts: RIVASTIGMIN ZEN 13.3MG/24H